Optimal Preclinical Conditions for Using Adult Human Multipotent Neural Cells in the Treatment of Spinal Cord Injury
Open Access
- 4 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5), 2579
- https://doi.org/10.3390/ijms22052579
Abstract
Stem cell-based therapeutics are amongst the most promising next-generation therapeutic approaches for the treatment of spinal cord injury (SCI), as they may promote the repair or regeneration of damaged spinal cord tissues. However, preclinical optimization should be performed before clinical application to guarantee safety and therapeutic effect. Here, we investigated the optimal injection route and dose for adult human multipotent neural cells (ahMNCs) from patients with hemorrhagic stroke using an SCI animal model. ahMNCs demonstrate several characteristics associated with neural stem cells (NSCs), including the expression of NSC-specific markers, self-renewal, and multi neural cell lineage differentiation potential. When ahMNCs were transplanted into the lateral ventricle of the SCI animal model, they specifically migrated within 24 h of injection to the damaged spinal cord, where they survived for at least 5 weeks after injection. Although ahMNC transplantation promoted significant locomotor recovery, the injection dose was shown to influence treatment outcomes, with a 1 × 106 (medium) dose of ahMNCs producing significantly better functional recovery than a 3 × 105 (low) dose. There was no significant gain in effect with the 3 × 106 ahMNCs dose. Histological analysis suggested that ahMNCs exert their effects by modulating glial scar formation, neuroprotection, and/or angiogenesis. These data indicate that ahMNCs from patients with hemorrhagic stroke could be used to develop stem cell therapies for SCI and that the indirect injection route could be clinically relevant. Moreover, the optimal transplantation dose of ahMNCs defined in this preclinical study might be helpful in calculating its optimal injection dose for patients with SCI in the future.Funding Information
- National Research Foundation of Korea (NRF-2016R1A5A2945889, NRF-2019R1F1A1060243)
- Korea Basic Science Institute (2020R1A6C101A191)
- Samsung Biomedical Research Institute grant (SMX1161411)
This publication has 47 references indexed in Scilit:
- In situ labeling of DNA reveals interindividual variation in nuclear DNA breakdown in hair and may be useful to predict success of forensic genotyping of hairInternational journal of legal medicine, 2011
- Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injuryProceedings of the National Academy of Sciences of the United States of America, 2010
- The Neural Stem Cell Line CTX0E03 Promotes Behavioral Recovery and Endogenous Neurogenesis After Experimental Stroke in a Dose-Dependent FashionNeurorehabilitation and Neural Repair, 2009
- Grafting of Human Bone Marrow Stromal Cells Into Spinal Cord InjurySpine, 2009
- Spinal Cord Injury Treatment With Intrathecal Autologous Bone Marrow Stromal Cell Transplantation: The First Clinical Trial Case ReportThe Journal of Trauma and Acute Care Surgery, 2008
- Functional Axonal Regeneration through Astrocytic Scar Genetically Modified to Digest Chondroitin Sulfate ProteoglycansJournal of Neuroscience, 2007
- Glial inhibition of CNS axon regenerationNature Reviews Neuroscience, 2006
- Myelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell DifferentiationJournal of Neuroscience, 2006
- Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNSNature Reviews Neuroscience, 2003
- A Sensitive and Reliable Locomotor Rating Scale for Open Field Testing in RatsJournal of Neurotrauma, 1995